NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,450.28 +243.15 (+1.34%) CRUDE OIL
79.18 +0.23 (+0.29%) GOLD FUTURES
2,313.20 +3.60 (+0.16%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,433.98 +1,587.39 (+3.46%)
Regeneron Pharmaceuticals, Inc. (REGN)
After hours:
| Previous close | 903.48 |
| Open | 900.00 |
| Bid | 937.18 x 100 |
| Ask | 939.38 x 200 |
| Day's range | 891.60 - 943.77 |
| 52-week range | 684.81 - 998.33 |
| Volume | |
| Avg. volume | 463,100 |
| Market cap | 103.311B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 26.97 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Regeneron Reports First Quarter 2024 Financial and Operating Results
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil
- GlobeNewswire
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseasesTARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA® HD (aflibercept) Injection 8 mg. The presentat
- GlobeNewswire
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRIS
